
Nuvalent (NUVL) Stock Forecast & Price Target
Nuvalent (NUVL) Analyst Ratings
Bulls say
Nuvalent is a clinical-stage biopharmaceutical company with a promising pipeline of small molecules targeting genetically validated kinase targets in cancer. With the recent acceptance of the NDA for neladalkib by the FDA for ALK+ NSCLC patients and the upcoming presentation of data at ASCO for NVL-520 and NVL-655, the company appears to be on track for commercial success. Additionally, with a strong balance sheet and continued pipeline development, the company's stock presents a compelling investment opportunity for potential growth.
Bears say
Nuvalent is a clinical-stage biopharmaceutical company that is developing small molecules for patients with cancer, with all of its operations in the US. While their preclinical data for their ROS1 inhibitor, zidesamtinib, shows potential, their ALK inhibitor, neladalkib, has only shown a modest response rate in heavily pre-treated patients and may not be able to compete with other ALK inhibitors. With a current revenue forecast of only $68MM for neladalkib's potential launch in 2027, and a risk-adjusted discount rate of 15-30%, the company's future outlook is not favorable.
This aggregate rating is based on analysts' research of Nuvalent and is not a guaranteed prediction by Public.com or investment advice.
Nuvalent (NUVL) Analyst Forecast & Price Prediction
Start investing in Nuvalent (NUVL)
Order type
Buy in
Order amount
Est. shares
0 shares